Chemotherapy in patients with advanced pancreatic cancer: Too close to death?

Supportive Care in Cancer

Volumn 21, Issue 1, 2013, Pages 157-163

  Frigeri, M ^a   De Dosso, S ^b   Castillo Fernandez, O ^c   Feuerlein, K ^b   Neuenschwander, H ^b   Saletti, P ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c Instituto Oncologico Nacional   (Panama)

Author keywords

Aggressiveness; End of life; Palliative chemotherapy; Pancreatic cancer

Indexed keywords

ALBUMIN; BILIRUBIN; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; ATTITUDE TO ILLNESS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG UTILIZATION; FEMALE; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SWITZERLAND;

EID: 84874106664     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1505-9     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. Cancer J Clin 60:277-300
2. Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607-2615
3. Cherny NJ, Abernethy AP, Strasser F et al (2009) Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. J Clin Oncol 27:5476-5486
4. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
5. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
6. Pelzer U, Schwaner I, Stieler J et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676-1681
7. Earle CC, Neville BA, Landrum MB et al (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22:315-321
8. Earle CC, Park ER, Lai B et al (2003) Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 21:1133-1138
9. Park JK, Yoon YB, Kim YT et al (2008) Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol 42:86-91
10. Nakachi K, Furuse J, Ishii H et al (2007) Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 37:114-120
11. Viganó A, Bruera E, Jhangri GS et al (2000) Clinical survival predictors in patients with advanced cancer. Arch Intern Med 160:861-868
12. Earle CC, Ayanian JZ (2006) Looking back from death: the value of retrospective studies of end-of-life care. J Clin Oncol 24:838-840
13. Näppä U, Lindqvist O, Rasmussen BH et al (2011) Palliative chemotherapy during the last month of life. Ann Oncol 11:2375-2380
14. Emanuel EJ, Young-Xu Y, Levinsky NG et al (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639-643
15. O'Brien ME, Borthwick A, Rigg A et al (2006) Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. Br J Cancer 95:1632-1636
16. Andreis F, Rizzi A, Rota L et al (2011) Chemotherapy use at the end of life. A retrospective single centre experience analysis. Tumori 97:30-34
17. Braga S, Miranda A, Fonseca R et al (2007) The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Psychooncology 16:863-868
18. Goncxalves J, Goyanes C (2008) Use of chemotherapy at the end of life in a Portuguese oncology center. Support Care Cancer 16:321-327
19. Keam B, Oh DY, Lee SH et al (2008) Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol 38:381-386
20. Sheffield KM, Boyd CA, Kuo Y-F et al (2011) End-of-life care in Medicare beneficiaries dying with pancreatic cancer. Cancer 117:5003-5012
21. Behl D, Jatoi A (2010) What do oncologists say about chemotherapy at the very end of life? Results from a semiquantitative survey. J Palliat Med 13:831-835
22. Earle CC, Neville BA, Ladrum MB et al (2005) Evaluating claims-based indicators of the end-of-life cancer care. Int J Qual Health Care 17:505-509
23. Smith TJ, Dow LA, Virago E et al (2010) Giving honest information to patients with advanced cancer maintains hope. Oncology 24:521-525
24. Helft PR (2005) Necessary collusion: prognostic communication with advanced cancer patients. J Clin Oncol 23:3146-3150
25. Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near end of life? A review of the prospective of those facing death from cancer. J Clin Oncol 24:3490-3496
26. Christakis N, Lamont E (2000) Extent and determinants of error in doctors' prognoses. Br Med J 320:469-473
27. Vigano A, Dorgan M, Buckingham J et al (2000) Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 14:363-374
28. Glare P, Virik K, Jones M et al (2003) A systematic review of physicians' survival predictions in terminally ill cancer patients. Br Med J 327:195-200
29. Maguire P (1985) Barriers to psychological care of the dying. Br Med J (Clin Res Ed) 291:1711-1713
30. Kao S, Shafiq J, Vardy J, Adams D (2009) Use of chemotherapy at end of life in oncology patients. Ann Oncol 20:1555-1559
31. Thorne SE, Bultz BD, Baile WF et al (2005) Is there a cost to poor communication in cancer care?: a critical review of the literature. Psychooncology 14:875-884
32. Maltoni M, Caraceni A, Brunelli C et al (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240-6248
33. Hauser CA, Stockler MR, Tattersall MHN (2006) Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer 14:999-1011
34. Hess V, Glimelius B, Grawe P et al (2008) CA 19-9 tumor marker response to chemotherapy in patients with pancreatic cancer enrolled in a randomized controlled trial. Lancet Oncol 9:132-138
35. Feliu J, Jiménez-Gordo AM, Madero R et al (2011) Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst 103:1613-1620